Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Ascendis Pharma A/S has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 4 distinct examiners and 4 distinct art units. This distribution shows a high level of variety in the examination process for the company's active applications.
FARRAR, LAUREN PENG is the busiest examiner, responsible for 1 pending office action. Because there are 4 pending office actions and 4 distinct examiners, the workload is divided such that each examiner handles a single matter. This ensures that the company's prosecution risks are diversified across four different individuals and technical groups.
The 4 distinct art units involved suggest that the company's innovations touch on several different aspects of Biotechnology & Pharmaceuticals. Managing multiple examiners requires a coordinated effort to maintain consistency in the company's overall patent strategy. Practitioners should be prepared to address the unique technical perspectives of each of the 4 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FARRAR, LAUREN PENG | 1 | 78.6% | +15.5% |
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
| ELENISTE, PIERRE PAUL | 1 | 35.5% | +31.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596832 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ELENISTE, PIERRE PAUL | 1d overdue |
| 17596831 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | MOSHER, ERIC PARKER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596832 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ELENISTE, PIERRE PAUL | 1d overdue |
| 18105460 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | JOHNSON, CHRISTOPHER LINDSAY | 34d |
| 18652601 | AUTO INJECTOR WITH DETECTION OF USED CARTRIDGE AND ASSOCIATED METHOD | FARRAR, LAUREN PENG | — |
| 18552656 | Use Of Long-Acting Growth Hormone For Treating Inflammation-Induced Diseases | HELLMAN, KRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 3783 | 1 |
| 1654 | 1 |
| 1691 | 1 |
| 1600 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18652601 | AUTO INJECTOR WITH DETECTION OF USED CARTRIDGE AND ASSOCIATED METHOD | FARRAR, LAUREN PENG | 3783 | DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18552656 | Use Of Long-Acting Growth Hormone For Treating Inflammation-Induced Diseases | HELLMAN, KRISTINA M | 1654 | §103§112DP | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18105460 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | JOHNSON, CHRISTOPHER LINDSAY | 1691 | — | Final Rejection | 34d | Pending | Feb 03, 2023 |
| 17596831 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | MOSHER, ERIC PARKER | 1600 | §102§103 | Final Rejection | — | Pending | Dec 20, 2021 |
| 17596832 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ELENISTE, PIERRE PAUL | 1622 | §103§112 | Final Rejection | 1d overdue | Pending | Dec 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial